GSK Deadline: GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm is reminding purchasers of GSK plc American Depositary Receipts (ADRs) of the upcoming lead plaintiff deadline for a class action lawsuit related to the company's alleged misleading statements regarding Zantac [1][2]. Group 1: Class Action Details - The class action lawsuit pertains to GSK ADRs purchased between February 5, 2020, and August 14, 2022, with a lead plaintiff deadline set for April 7, 2025 [1][2]. - Investors who purchased GSK ADRs during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. Group 2: Allegations Against GSK - The complaint alleges that GSK misrepresented the reasons for withdrawing Zantac from the market, claiming it was based on available information and regulatory correspondence, while in reality, GSK had known about the source of NDMA for nearly 40 years [4][5]. - GSK assured investors that there was no causal link between ranitidine therapy and cancer, which the lawsuit claims was materially false or misleading [4][5]. - The lawsuit asserts that GSK concealed an internal study implicating its liability to Zantac users, leading to investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [3].